Agenus (AGEN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
13 May, 2026Voting matters and shareholder proposals
Proposal 4 seeks approval for a one-time exchange of underwater stock options held by employees, consultants, and non-employee directors for new options, with executive and director options priced at a 50% premium to fair market value on the exchange date.
The exchange is structured as a one-for-one share replacement, with no increase in the aggregate number of outstanding options.
Approval requires a majority of votes cast by stockholders present in person or by proxy; abstentions and broker non-votes will not affect the outcome.
The Board recommends a vote in favor of Proposal 4.
Executive compensation and say-on-pay
Executives and non-employee directors will receive replacement options with a strike price at 150% of the exchange date’s fair market value, aligning their compensation with future stock price appreciation.
Other employees and consultants will receive options at fair market value, restoring retention and motivation value.
Executives have elected to receive both base and annual bonus compensation entirely in stock and options, with no cash component.
The compensation committee selected this structure to avoid incremental cash outlay and to ensure executives benefit only after significant stock price appreciation.
Board of directors and corporate governance
The compensation committee evaluated alternatives and determined the one-for-one exchange with a premium strike for executives best aligns with stockholder interests.
Executive officers and non-employee directors are eligible to participate if they hold eligible options and remain in service through the exchange date.
Latest events from Agenus
- BOT + BAL shows unprecedented efficacy in MSS colon cancer, with a pivotal Phase 3 trial fully funded.AGEN
Corporate presentation31 Jul 2026 - Biotech registers 2.1M shares for resale by investor; lead immunotherapy in Phase 3 trials.AGEN
Registration filing20 Jul 2026 - $340M secured for pivotal Phase 3 BOT + BAL trial in MSS colon cancer, targeting $7B+ market.AGEN
Investor update16 Jul 2026 - BOT/BAL shows strong efficacy as financials improve and capital proposals advance.AGEN
Q1 20259 Jul 2026 - $91M Zydus deal boosts liquidity as BOT/BAL advances to Phase 3, but funding risks persist.AGEN
Q2 20258 Jul 2026 - Zydus collaboration secures manufacturing and capital, enabling global BOT/BAL access expansion.AGEN
Status update8 Jul 2026 - Strong BOT/BAL data, improved cash, but partnership losses raise going concern risks.AGEN
Q2 20248 Jul 2026 - All proposals passed; focus is on BOT/BAL development, access expansion, and financial stability.AGEN
AGM 202616 Jun 2026 - Q1 2026 delivered profitability, global asset expansion, and key regulatory and financial gains.AGEN
Q1 202611 May 2026